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Purpose: Gastric cancer has the highest incidence rate
among cancers in Asia. The advanced type of signet ring cell
carcinoma has poor prognosis compared to other types of
gastric cancer. The immuno-gene therapy with cytokine-based
tumor vaccines has not yet been investigated for gastric cancer.
The granulocyte macrophage colony-stimulating factor (GM-
CSF)-based tumor vaccine has been demonstrated as the most
potent stimulator for specific and long-lasting systemic tumor
immunity. Materials and Methods: In the present study, KATO
III cells, the human signet ring cell gastric carcinoma cell line,
were genetically modified by the transduction with the human
GM-CSF cDNA or the modified hGM-CSF in replication-
deficient retroviruses. The genomic integrations and mRNA
expressions of the transgenes were determined by Southern
and Northern blot analyses. Results: Wild type (wt) or
modified hGM-CSF was integrated into the genome of KATO
III cells. The modified hGM-CSF mRNA was more stable than
that of wt. The KATO III cells with the modified hGM-CSF
produced higher level of hGM-CSF (12.4 - 19 ng/10
6 cells/48
hrs) than that with wt hGM-CSF, when determined by
enzyme-linked immunosorbent assay (ELISA). The secreted
recombinant hGM-CSF could support the proliferation of the
GM-CSF-dependent cell line, indicating that the hGM-CSF
secreted by the transduced KATO III cells has biological
activities. Irradiated, transduced KATO III cells continued to
secret hGM-CSF without proliferation. Conclusion: Our results
suggest that GM-CSF secreting KATO III cells could be tested
for the treatment of gastric cancer as an allogeneic tumor
vaccine as a part of immunotherapeutic treatment.
Key Words: Human granulocyte macrophage colony-stimulating
factor transduced gastric cancer cell line, allogeneic gastric
cancer cell vaccine, immuno-gene therapy
INTRODUCTION
Gastric cancer has the highest incidence rate in
East Asia, including Korea and Japan.
1 There are
strong correlations between the high incidence
rate of gastric cancer and the environment,
especially childhood environment, diet, smoking,
and Helicobacter pylori infection.
2 Although the
incidence rate of gastric cancer has been declined,
it is the second cause of cancer-related death
worldwide and the fourth common cancer.
2
Surgery, chemotherapy and radiotherapy are
generally applied for cancer therapy. However,
the treatment with surgery alone has high rate of
failure, and chemotherapy and radiotherapy have
not improved the survival rates when used
separately. Cancer vaccination is an active immu-
notherapy to induce active anti-tumor immunity
of cancer patients by exposing the tumor antigens
to their immune system. Cytokine-modified cell-
based tumor vaccines have been clinically tested
as immuno-gene therapy and major forms of
cancer vaccines. Among genetically modified cell
based-tumor vaccines to secrete cytokines, GM-
CSF has been the most potent stimulator for
specific and long-lasting systemic tumor immunity.
3
GM-CSF is a critical factor for inducing differen-
tiation of primitive hematopoietic precursors into
dendritic cell (DC), the most potent professional
antigen-presenting cells (APC) that initiates CD4
+
and CD8
+ T cell response.
4-6 Paracrine GM-CSF
from tumor cell vaccines may induce anti-tumor
immune response by promoting local DC differ-
entiation at vaccine site to induce local inflamma-
tory response to eliminate tumors.
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Autologous GM-CSF secreting tumor vaccines
have cured the established tumors in mice and
shown promising results in patients with melanoma
and prostate and renal cell carcinomas.
3,7-9 Since
autologous GM-CSF secreting tumor vaccine cells
display all the relevant tumor antigens, immuni-
zation with these cells will induce anti-tumor
immunity to patients. Nevertheless, adequate
numbers of these cells are rarely available and are
labor intensive, because de novo gene transfer of
each patient and certification of each patient's lot
of vaccine cells are expensive and time-con-
suming.
To circumvent the limitations of autologous
tumor vaccines, allogeneic tumor vaccines have
been developed and reported to have numerous
advantages over autologous cell counterparts. The
rationale for allogeneic tumor vaccine includes the
following. First, many tumor antigens seem to be
commonly expressed among different tumors.
10,11
Second, professional APCs are responsible for
priming CD4
+ and CD8
+ T cells to generate
systemic anti-tumor immunity.
12,13 It has been
demonstrated that tumor-specific CD8
+ T cells are
activated by cross-priming mechanism. Third, the
efficacy of allogeneic tumor vaccine has been
validated in animal models.
7 Also, the irradiated
allogeneic GM-CSF transduced tumor cell vaccine
has been shown to be safe and induce dose-
dependent systemic anti-tumor immunity in
clinical trial of pancreatic adenocarcinoma, prostate
cancer, lung cancer, leukemia and myeloma, as
measured by increased post-vaccination delayed
type hypersensitivity (DTH) response against the
autologous tumor cells,
3,14 indicating that immu-
nizing tumor cells do not need to be HLA
compatible with the host to generate tumor
antigen-specific immunity. The trade-marked GM-
CSF-based vaccines, GVAX
TM series of cancer
vaccines, have been successful in early clinical
trials.
15 Prostate cancer vaccine has been pro-
gressed to the phase III clinical trials while the
pancreatic cancer, lung cancer, leukemia and
myeloma vaccines have obtained positive phase II
results.
15
Immuno-gene therapies with cytokine-based
tumor vaccines to treat gastric cancer have not so
far been tested, even though many researchers
have tried the cytokine-modified cancer cell
immunotherapies for various types of cancers and
observed positive pre-clinical and clinical results
with GM-CSF-modified cancer vaccines.
5,12,15 In
this study, we established human gastric cancer
cell lines that stably produced hGM-CSFs with
replication-deficient retroviruses containing wt
hGM-CSF cDNA or modified hGM-CSF. The
modified hGM-CSF transgene transduced KATO
III cells secreted higher levels of hGM-CSF than
wt hGM-CSF transgene transduced cells. Also,
this recombinant hGM-CSF had biological activity
when tested with GM-CSF dependent cell growth
analysis. These results indicate that the GM-CSF
secreting KATO III cells can be tested as a
potential GM-CSF secreting allogeneic tumor
vaccine to treat gastric cancer as a part of an
immunotherapeutic treatment.
MATERIALS AND METHODS
Vectors and cell lines
Retroviral vectors, pLNCX and pLXIN (Clontech,
Palo Alto, CA, USA), were used. Human GM-CSF
cDNA was obtained from American Tissue
Culture Collecton (ATCC No. 39754). KATO III
cells, the human gastric cancer cell line (Korean
Cell Line Bank No 30103, Seoul, Korea),
16 and
PA317 packaging cell lines were maintained in
RPMI 1640 medium and Dulbecco's modified
Eagle's medium, respectively, supplemented with
10% heat inactivated fetal bovine serum, 100 IU/
mL penicillin and 100 g/mL streptomycin, and μ
grown at 37 with 5% CO2.
Cloning and site-directed mutagenesis of hGM-CSF
gene
The hGM-CSF cDNA (p91023, ATCC No. 39745)
was cloned into Hpa I site of pLNCX retroviral
vector, and Hpa I and Xho I sites of pLXIN
retroviral vector, resulting in pLNCGM and
pLGMIN, respectively. Green fluorescence protein
(GFP) gene was cloned into Hpa I and BamH I
sites of retroviral vectors, pLNCX and pLXIN,
respectively. To modify the hGM-CSF gene, hGM-
CSF AUG start codon flanking sequences were
replaced to a partial Kozak sequences, and 3’-endhGM-CSF Transduced-Gastric Cancer Cell Vaccine
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UTR of AUUUA repeat sequences of the hGM-
CSF gene was replaced to AUGUA sequences
from nt 672 to 688, and deleted from nts 647 to
671 and from nts 689 to 711 sequences using a
recombinant polymerase chain reaction (PCR).
17 In
brief, to modify the AUG start codon flanking
sequences and 3'-end UTR of hGM-CSF cDNA,
hGM-CSF cDNA in pcDNA3 vector was incubated
with sense primer GC6 (5’-CGGGATCCGCCAC
CATGTGGCTGCAGAGCCTGCTGCTC-3’), which
contains Kozak sequence and BamH I site and
binds nt 9 to 32 of hGM-CSF cDNA, and anti-
sense primer GC10 (5’-TACATACATACATACATA
TTACTGATTTCTGTCAGTATAA-3’), which binds
nt 626 to 686 with the deletion from 647 to 671
and the modification from nt 672 to 688, in PCR
buffer at 94 for 1 min, 54 for 1 min, and 72
for 1 min for 25 cycles. Also, hGM-CSF cDNA in
pcDNA3 vector was incubated with sense primer
GC11 (5’-ATGTATGTATGTATGTATTCAAGATG
TTTTACCGT-3’), which binds to nts 669 to 733
with the deletion from 689 to 711 and the
modification from nt 672 to 688, and anti-sense
primer GC9 (5’-CGGGATCCGTGTGATGGATAT
CTGCAGAATTC-3’), which binds pcDNA vector
sequences with BamH I site, as described above.
The resulting 680 bp and 120 bp PCR fragments
were purified and combined for recombinant PCR
using 94 for 1 min, 42 for 1 min, and 72 for
1 min for 25 cycles, with primers GC6 and GC9.
The 750 bp amplified PCR product was purified
and cloned into Hpa I and BamH I sites of pLNCX
and pLXIN retroviral vectors, resulting in
pLNCGMH and pLGMHIN, respectively. The
entire PCR derived regions were sequenced to
confirm the presence of the specific mutations and
the absence of other mutations.
Gene transfer to KATO III cells
Wt and modified hGM-CSFs and GFP genes in
pLNCX and pLXIN vectors were transfected to
PA317 packaging cell line by lipofectamine
reagent (Invitrogen
TM). The hGM-CSF containing
retrovirus particles were harvested and then
infected to KATO III cells in the presence of 8 g/ μ
mL of polybrene. The colonies of transduced
KATO III cell were selected in media containing
0.5 mg/mL of G418 and cultured. RT-PCRs with
total RNA extracts were performed using hGM-
CSF specific primers to detect the expression of
hGM-CSF mRNA.
Enzyme linked immunosorbent assay (ELISA)
The concentration of hGM-CSF secreted from
transduced KATO III cells was determined by
hGM-CSF ELISA kit (Endogen, Woburn, MA,
USA).
Southern blot and Northern blot analyses
Chromosomal DNA was extracted by Easy-
DNA
TM (Invitrogen
TM) according to manufacturer's
instruction. Thirty g of chromosomal DNA was μ
digested with Xho I, resolved in 0.8% agarose gels
and transferred to nylon membrane. The DNA on
the membrane was hybridized with
32P-labeled
random-primed probe specific for GM-CSF
sequences. To analyze hGM-CSF mRNA, total
RNA was extracted by RNA stat 60 (Tel-test, Inc.,
USA) according to manufacturer's instruction.
Twenty-five g of total RNA was denatured and μ
electrophoresed through 1% agarose gel
containing formaldehyde, and blotted onto nylon
membrane. The GM-CSF mRNA on the
membrane was hybridized with
32P-labeled
random-primed probe specific for GM-CSF.
Irradiation
The transduced KATO III cells (3 × 10
6 cells)
were irradiated twice with 30 Gray of -ray and γ
then incubated at 37 with 5% CO2. Cell pro-
liferation was monitored by cell count every 2
days.
Bioactivity of recombinant hGM-CSF
AML-193 (acute myeloid leukemia cell), GM-
CSF dependent leukemic cell line,
18 was used to
test the biological activity of recombinant hGM-
CSF. In brief, AML-193 cells were cultured in the
presence of transduced KATO III cell culture
supernatant, which contains the recombinant
hGM-CSF secreted. AML-193 cell proliferation
was monitored by
3H-thymidine uptake.Hee-Young Kim, et al.
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RESULTS
Establishment of the wild type and modified
hGM-CSF transduced KATO III cells
Replication-defective retroviral vector, pLXIN
(Clontech), that expresses foreign gene under the
control of long terminal repeat (LTR) promoter
with additional attenuated internal ribosome
entry site (IRES) and neomycin-resistance gene to
ensure the expression of foreign gene after G418
selections, was used to construct the pLGMIN that
contains cloned wt hGM-CSF cDNA. The retro-
viruses with wt hGM-CSF cDNA from the
pLGMIN transfected-PA317 packaging cells were
infected into KATO III cells to select the hGM-CSF
cDNA transduced KATO III cells. However, the
hGM-CSF (452 - 600 pg/10
6 cells/48 hrs) secreted
from transduced KATO III cell with LGMIN
vector was too low for therapeutic doses (Table 1).
To increase the expression of hGM-CSF, we
modified the AU rich element in 3'-end UTR of
the hGM-CSF gene (Fig. 1) to lengthen the half-life
of hGM-CSF mRNA in vitro by blocking the
Table 1. hGM-CSF Secretion from the Wild Type and Modified hGM-CSF-Transduced KATO III Cells
LGMIN-transduced KATO-III cells LGMHIN-transduced KATO-III cells
Clone No. Concentration Clone No. Concentration
LGMIN 1 0.459 LGMHIN 1 12.4
LGMIN 2 0.559 LGMHIN 2 13.0
LGMIN 9 0.553 LGMHIN 4 15.5
LGMIN 10 0.483 LGMHIN 8 12.6
LGMIN 11 0.458 LGMHIN 12 15.6
LGMIN 14 0.484 LGMHIN 13 17.5
LGMIN 15 0.452 LGMHIN 14 16.7
LGMIN 17 0.477 LGMHIN 18 19.0
LGMIN 19 0.600 LGMHIN 19 14.5
ELISA was performed to detect hGM-CSF from cell culture supernatant using human GM-CSF ELISA kit (Endogen,
Woburn, MA, USA). LGMIN- and LGMHIN-transduced KATO-III cells were incubated for 48hrs and supernatant were
collected. Concentration was ng/10
6 cells/48 hrs.
Fig. 1. Targeted mutagenesis of human GM-CSF sequence. To increase the hGM-CSF expressions, both the 5’-end start
codon flanking sequences (A) and 3’-end UTR (B) were mutated using recombinant PCR techniques. (A) The suboptimal
AUG start codon flanking sequences were replaced to a part of Kozak sequences. (B) AUUUA repeat sequences in 3’-end
UTR of the hGM-CSF gene were mutated to AUGUA repeat sequences (nts 672-688) and deleted (nts 647-671 and 689-711).
A
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post-transcriptional degradation.
17 In addition to
the modified 3'-end UTR, we also modified the
5'-end AUG start codon flanking sequence to a
partial Kozak sequences (Fig. 1) to up-regulate the
translation efficiency of hGM-CSF mRNA.
19 Thus,
KATO III cells were transduced with LGMHIN,
the retroviruses with modified hGM-CSF cDNA,
as described above. The hGM-CSF secreted from
modified hGM-CSF transduced KATO III cells
was 12 - 19 ng/10
6/48 hrs (Table 1). Since it has
been suggested that the amount of secreted hGM-
CSF for therapeutic uses needs to be moderate but
not too high or low,
20 the hGM-CSF secreted from
the presently modified hGM-CSF transduced
KATO III cells was in the almost right range
although a little low. Therefore, the established
hGM-CSF secreting transduced KATO III cells in
this study could be tested for gastric cancer
immunotherapy.
Chromosomal integration of hGM-CSF gene, mRNA
expressions, and hGM-CSF secretion
To test whether hGM-CSF was integrated into
the chromosome of transduced KATO III cells,
genomic DNAs of two representative KATO III
cell clones, containing LGMIN or LGMHIN, were
analyzed by Southern blot analysis (Fig. 2). Due
to their random integration sites and single Xba
I site in pLXIN vector, when digested with Xba
I, a single band of various sizes would indicate
that hGM-CSF was integrated as a single copy. As
expected, each clone of transduced KATO III cells
showed a single band of the hGM-CSF gene that
was different between two clones (Fig. 2). After
several passages, hGM-CSF transduced KATO III
cells were found to constantly secrete the amount
of hGM-CSF similar to that seen in Table 1 (data
not shown), indicating that hGM-CSF transgenes
containing KATO III cells could stably express
hGM-CSF through integrated hGM-CSF.
Next, we examined mRNA expressions of the
wt and modified hGM-CSFs by Northern blot
analysis (Fig. 3). Since the cloned wt and modified
hGM-CSFs cDNAs in pLXIN vector have their
own polyadenylation site, wt and modified hGM-
CSF mRNAs could be expressed as two mRNA
species. One is the authentic wt or modified hGM-
CSF mRNAs and the other is bicistronic mRNAs
which contain the wt or modified hGM-CSF and
IRES sequences and the neomycin resistance gene.
With the hGM-CSF specific probe, we detected
two mRNA species which were approximately 3.6
and 0.9 kbs in length (data not shown). The
expressions of 3.6 and 0.9 kbs hGM-CSF mRNAs
appeared to be not significantly different between
the wt and modified hGM-CSF mRNAs (Fig. 3,
data not shown), suggesting that hGM-CSF
mRNA was actively synthesized in the wt and
modified hGM-CSF transduced KATO III cells.
Because of no noticeable differences in the
expression levels between the wt and modified
hGM-CSF mRNAs (Fig. 3), we next compared the
stability of the wt and modified hGM-CSF
mRNAs by treating the transduced KATO III cells
with 2.5 mg/mL of actinomycin-D for 3 hrs to
block new mRNA synthesis (Fig. 4), and the
intensities of modified hGM-CSF mRNA were
stronger than those of wt hGM-CSF mRNAs by
the treatment (Fig. 4), indicating that modified
hGM-CSF mRNAs were stable and not degraded
easily like wt mRNA.
17 Therefore, the modified
hGM-CSF-transgene transduced KATO III cells
Fig. 2. Chromosomal integrations of the wt and modified
hGM-CSF transgenes in the transduced KATO III cells.
Southern blot analysis was performed to detect the
integrated wt and modified hGM-CSF transgenes in the
respective transduced KATO III cells. Chromosomal DNA
was isolated from two representative clones of LGMIN-
and LGMHIN-transduced KATO-III cells. Thirty g of Xba μ
I-digested chromosomal DNA was resolved in 0.8%
agarose gels and transferred to nylon membrane. The
DNA on the membrane was hybridized with random-
primed
32P-labeled GM-CSF specific probe and subjected
to autoradiography.Hee-Young Kim, et al.
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would appear to secrete more hGM-CSFs and/or
longer period of time. As expected, the modified
hGM-CSF transduced KATO III cells continued to
secrete hGM-CSF in the presence of actinomycin-
D, indicating that the already existing hGM-CSF
mRNA continues to be translated to secrete
hGM-CSF (data not shown).
Biological activity of hGM-CSF from transduced
KATO III cells
Since we modified only the 5’- and 3’-ends of
UTR of hGM-CSF cDNA (Fig. 1), the hGM-CSF
secreted from the wt and modified hGM-CSF
should have same biological activities. To test the
above contention, the proliferation of AML-193
cell, the GM-CSF dependent leukemic cell line,
was monitored by
3H-thymidine uptake (Fig. 5).
18
Thus, the culture supernatant from the clone
number 18 of transduced KATO III cells, which
secreted 18 - 20 ng/10
6 cells/48 hrs of hGM-CSF
(Table 1), was applied to AML-193 cells. As
shown in Fig. 5, AML-193 cells were found to pro-
liferate by the addition of the culture supernatant,
Fig. 3. The hGM-CSF mRNA expressions in the wt and
modified hGM-CSF transduced KATO III cells. Northern
blot analysis was performed to detect the wt and modified
hGM-CSF mRNAs in the respective transduced KATO III
cells. Total RNA was isolated from four representative
clones of LGMIN- and LGMHIN-transduced KATO III
cells. Transduced KATO III cells with LGFPIN, GFP-con-
taining retrovirus, were used as a negative control. Twenty-
five g of total RNA was denatured and electrophoresed μ
through 1% agarose gel containing formaldehyde and
transferred to nylon membrane. The GM-CSF mRNA on
the membrane was hybridized with random-primed
32P-
labeled GM-CSF specific probe and subjected to
autoradiography. 18S ribosomal RNAs are indicated as a
loading control.
Fig. 4. The stabilities of wt and modified hGM-CSF mRNAs
in the wt and modified hGM-CSF transduced KATO III
cells. Northern blot analysis was performed to compare
the mRNA stabilities of wt and modified hGM-CSF
mRNAs. LGFPIN transduced KATO III cells were used as
a negative control. Two representative clones of LGMIN
and LGMHIN transduced KATO III cells were treated
with 2.5 mg/mL of actinomycin-D for 3 hrs, and total
RNA was isolated. Twenty-five g of total RNA was μ
denatured and electrophoresed through 1% agarose gel
containing formaldehyde, and blotted onto nylon mem-
brane. GM-CSF mRNA on the membrane was hybridized
with random-primed
32P-labeled GM-CSF-specific probe
and subjected to autoradiography. 0.9kbs GM-CSF mRNAs
from LGMIN and LGMHIN transduced KATO III cells are
indicated as squares and asterisks, respectively. 18S
ribosomal RNAs are indicated as a loading control.
Fig. 5. Proliferation of GM-CSF dependent leukemic cells
by the addition of recombinant hGM-CSF from LGMHIN
transduced KATO III cells. To examine biological activity
of the recombinant hGM-CSF, culture supernatant from a
clone 18 of LGMHIN-transduced KATO III cells was
added to AML-193 cells (GM-CSF dependent leukemic cell
line) and proliferation of AML-193 cells was monitored by
3H-thymidine uptake.hGM-CSF Transduced-Gastric Cancer Cell Vaccine
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confirming biological activities of the recombinant
hGM-CSF.
hGM-CSF secretions by the irradiated, transduced
KATO III cells
Since we showed that the modified hGM-CSF
mRNA is more stable than the wt hGM-CSF
mRNA (Fig. 4), the modified hGM-CSF transduced
KATO III cells were irradiated to test whether the
irradiated KATO III cells with transgenes continue
to secrete hGM-CSF without cell proliferation.
After twice the irradiation by 30 Gray of -ray, the γ
KATO III cells no longer proliferated for 8 days
(data not shown), indicating that irradiation by 30
Gray of -ray twice is sufficient to stop prolifera γ -
tion of KATO III cells. Recombinant hGM-CSF
was continuously secreted from the irradiated,
transduced KATO III cells (Table 2), suggesting
that these hGM-CSF secreting KATO III cells
could be tested as a potential allogeneic gastric
tumor vaccine to treat gastric cancer.
DISCUSSION
To treat cancers, several strategies of gene
therapies, including induction of malignant cell
death, modulation of immune response to tumors,
and reversion of malignant process by correcting
the genetic abnormalities, have been applied. In
addition, gene replacement, anti-sense therapy,
cytotoxic gene therapy, immune-gene therapy,
and drug resistance transfer have also been
applied. Immunotherapy to modulate immune
response to a particular tumor can be divided into
passive and active immunotherapies. Passive
immunotherapy involves the transfer of immune
effectors such as tumor-specific T cells and tumor-
specific antibodies. Immunizations with killed
tumor cells or purified tumor antigens, or with
tumor antigen-transfected or -pulsed professional
antigen presenting cells (APCs) are parts of active
immunotherapies. Cytokine- or costimulatory-,
such as the B7 gene, modified cancer cell vaccines
also constitutes active immunotherapies.
It had been reported that the advanced type of
signet ring cell carcinoma has poor prognosis
compared to other types of gastric cancer.
21 There-
fore, alternative or supplementary treatments to
augment chemotherapy or surgery, such as
immunotherapy, are in great demand. KATO III
cells, the signet ring cell gastric carcinoma cell
line, are diffuse type undifferenciated adenocar-
cinoma cells with the deletion of p53, the
amplification of K-sam and c-met oncogenes, and
the mutations of E-cadherin
1,16,22,23 and express
HLA-ABC, HLA-A2/A28, HLA-B7/B27, HLA-DR
and HLA-DQ.
24 Since KATO III cells do not
express GM-CSF mRNA when infected with H.
pylori
25 and do not secrete hGM-CSF, KATO III
cells were selected in this study to genetically
modify and secrete hGM-CSF, as a candidate of
hGM-CSF-modified human gastric cancer cell
vaccine.
Since retroviruses do not have lytic cycle and
stably express the chromosome-integrated foreign
gene in infected cells, retroviruses are the most
commonly utilized vectors to prepare cytokine-
secreting tumor vaccines. The fact that PA317
packaging cell line, used in this study, produced
high titer of hGM-CSF cDNA containing retro-
Table 2. hGM-CSF Secretion from the Irradiated, hGM-CSF-Transduced KATO III Cells
Clone No. Control After irradiation
LGMIN 2 0.509 0.352
LGMIN 19 0.618 0.493
LGMHIN 13 10.10 9.63
LGMHIN 18 10.50 7.93
Two representative clones of LGMIN- and LGMHIN-transduced KATO-III cells were selected. Each set of 3 × 10
6 cells were
irradiated two times with 30 Gray of -ray, then incubated at 37 with 5% CO γ 2 for 2 days. ELISA was performed to detect
hGM-CSF from cell culture supernatant using human GM-CSF ELISA kit (Endogen, Woburn, MA, USA). Concentration was
ng/10
6 cells/48 hrs.Hee-Young Kim, et al.
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viruses in the absence of helper virus with
amphotropic host range indicates that various
types of cells, including mouse, rat, cat, dog and
human cells, such as hematopoietic progenitor
cells from human bone marrow, could be infected.
26
Among two pLNCX and pLXIN retroviral vectors
tested to deliver the hGM-CSF gene into KATO III
cells, we could not obtain wt hGM-CSF
transduced KATO III cell clones using pLNCX
vector even though we were able to detect small
amount of hGM-CSF secreted from pooled KATO
III cells with transgene (data not shown).
Although modified hGM-CSF transduced KATO
III cell clones were obtained using pLNCX vector
and secreted amounts of hGM-CSFs were
detectable, the amount of secreted hGM-CSF was
still too low for GM-CSF secreting cancer vaccine
trial (data not shown). We speculate that some
hGM-CSF were lost from LNCGM and LNCGMH
retroviruses from transduced, G418 selected-
KATO III cells during the selection processes that
select only by neomycin resistance. On the other
hand, neomycin resistance gene in LGMIN and
LGMHIN retroviruses was expressed under the
control of 5'-end LTR promoter through attenuated
IRES from the same transcript to ensure the
expression of wt and modified hGM-CSF after
G418 selection.
The expressions of most cytokines or growth
factors are modulated by self-regulatory mechanism
by controlling mRNA level. Most cytokine
mRNAs, including GM-CSF, contain adenosine-
uridine (AU)-rich element (AREs) in the 3’-end
untranslated region (UTR) which is the target site
for RNA binding protein to control the expression
level through the regulated mRNA stabilities.
17,27
The AREs, pentameric AUUUA sequences, in
3'-UTR regions of cytokine genes are AUUUA
instability elements that are targeted by RNA
binding protein, adenosine-uridine binding factor
(AUBF), to prevent rapid decay of mRNAs in
activated cells.
17,27-29 When AUBF activity is
depleted, GM-CSF mRNA decay is accelerated
from 90 min half-life to 20 min, indicating that
mRNA stability is regulated through changes in
half-lives.
28,29 The mutations of this ARE increase
the GM-CSF mRNA stability by 5-fold, thus
elevating the expression of GM-CSF without
affecting the biological activities.
16,17 Also, due to
the suboptimal start codon, cytokine mRNAs are
poor initiators of translation to modulate the yield
of cytokine.
19 In the present study, since hGM-CSF
secretion by wt hGM-CSF transduced KATO III
was too low to modulate immune responses, we
transduced KATO III cells with modified
transgene in which both the 5’-end suboptimal
start codon and 3’-end AUUUA instability
elements of hGM-CSF were mutated to increase
the steady state level, resulting in 20- to 40-fold
increases of hGM-CSF secretion (Table 1).
It had been demonstrated that vaccines pro-
ducing 40ng of GM-CSF/10
6 cells/24hrs induced
maximal systemic immunity.
20 The modified
hGM-CSF transduced KATO III cells produced
12- 19 ng/10
6 cells/48 hrs (Table 1), which is
slightly low for the maximal systemic immunity,
nevertheless, still in the range to be effective.
20
Therefore, we suggest that it would be worthwhile
to test the irradiated, hGM-CSF secreting KATO
III cells as an allogeneic tumor vaccine to treat
gastric cancer as a part of immunotherapeutic
treatment.
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